glp-1 receptor agonists for weight loss Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH Beyond Weight Loss: Other Benefits

In 2016, concerns regarding retinopathy associated with GLP-1 were first raised in the Semaglutide Unabated Sustainability in Treatment of T2DM (SUSTAIN) 6 trial with semaglutide [89]

Patients with eating disorders, extreme frailty or very low BMI may experience more harm than benefit

However, some healthcare providers may prescribe GLP-1s off-label to people with type 1, as research indicates they can improve blood sugar levels, manage weight, reduce the need for insulin, and offer protection for the heart and kidneys

Who Should Consider Prescription GLP-1 Options Over OTC Alternatives Individuals with BMI over 27, metabolic syndrome, prediabetes, or type 2 diabetes have the strongest clinical evidence supporting prescription GLP-1 therapy

Cost-effectiveness and health economic implications The elevated cost of acquisition of GLP-1 receptor agonists convey major challenges for healthcare systems, with yearly treatment expenses between $10,000 and $15,000 USD, markedly surpassing those of conventional diabetic drugs (Kong et al